NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/13/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization11,186 mln
Float43.55 mln
Earnings Date08/10/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.44
Borderline
1-Year Forecast
270
Modest upside
Relative Strength
95
/ 100
Top performer
Debt / Equity
4.03
Highly leveraged
ROE
-275
Deeply negative
Business Description
Axsome Therapeutics is a US-based pharmaceutical company focused on developing and commercializing treatments for brain and nervous system conditions. Its current lineup of approved medicines addresses major depression, excessive daytime sleepiness, and migraines. The company also has several drugs in clinical testing aimed at conditions such as Alzheimer's agitation, fibromyalgia, narcolepsy, and attention deficit disorder, among others. Founded in 2012 and headquartered in New York, Axsome works with partners like Duke University to advance its research pipeline.
